CSI Market
Sign In | Register

Verve Therapeutics Inc (VERV) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access VERV quarterly Cash Flow →
Tracking cash flow results across Verve Therapeutics Inc to helps illustrate how Dec 31 2024's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2024)
12 Months 		(Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-198.71
Depreciation & amortization6.75
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue5.31
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation43.26
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Amortization Of Premium On Marketable Securities-
Change In Fair Value Of Preferred Stock Tranche Liabilities-
Change In Fair Value Of Antidilution Rights-
Provision For Lease Losses-
Net Amortization Of Premium Accretion Of Discount On Marketable Securities-12.41
Change In Fair Value Of Success Payments Liabilities-1.54
Increase Decrease In Operating Lease Liability-4.93
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables2.64
Increase (Decrease) in Accounts Payable-1.83
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities4.63
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-8.09
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities7.21
Discontinued operations0.00
Net Cash flow from Operating Activities-157.69
Investing Activities
Capital Expenditures-3.74
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Payments to Acquire Marketable Securities-424.00
Real Estate Investments0.00
Maturities Of Marketable Securities502.61
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities74.88
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.07
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.26
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceed From Shareholder Loan-
Employee Stock Ownership Plan E S O P Cash Contributions To E S O P-
Issuance Of Share Under Employee Stock Purchase Plan1.27
Proceeds From Issuance Of Common Shares Net Of Commissions-
Proceeds From Issuance Of Common Stock Net Of Issuance Costs46.73
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities49.20
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-161.43
Total Cash Flow-33.62
4 historic quarters locked

Sign in to unlock the full Verve Therapeutics Inc cash flow history.

Sign In Create Free Account

About Verve Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20241231)
  • Filed with the SEC: February 27, 2025
  • Source: verv-20241231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-25-028376

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License